Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management

Medicine & Life Sciences

• Primary Myelofibrosis 100%
• Risk Management 87%
• INCB018424 55%
• Mutation 44%
• Karyotype 36%
• Essential Thrombocythemia 35%
• Survival 29%
• Extramedullary Hematopoiesis 25%
• Polycythemia Vera 22%
• Splenomegaly 19%
• 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 17%
• N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 17%
• Fedratinib 17%
• Anemia 14%
• Reticulin 12%
• Bone Marrow Examination 12%
• Cachexia 10%
• Y Chromosome 10%
• Hydroxyurea 10%
• Splenectomy 9%
• Hematopoietic Stem Cells 8%
• Cytogenetics 8%
• Platelet Count 8%
• Therapeutics 7%
• Spleen 6%
• Collagen 6%
• Fibrosis 6%
• Extremities 6%
• Stem Cells 6%
• Bone Marrow 6%
• Direction compound 6%
• Observation 6%
• Radiotherapy 6%
• Clinical Trials 5%
• Transplants 5%
• Cytokines 5%
• Bone and Bones 5%
• Drug Therapy 5%
• Pain 5%
• Pharmaceutical Preparations 3%
• Neoplasms 2%